Key result
Preoperative GLP-1 RA use investigated for links to weight loss after bariatric surgery.
Why the study?
Does preoperative use of GLP-1 RAs improve weight loss outcomes in patients undergoing bariatric surgery?
Does preoperative use of GLP-1 RAs improve weight loss outcomes in patients undergoing bariatric surgery?
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In our study, we saw no such effect. Those taking GLP-1 receptor agonists, who presumably lost weight from the medications before surgery, turned out to lose additional weight the same as the GLP-1 receptor agonist-naive patients.”
“It is not a zero-sum game. We should not think of obesity treatment as a competition between medicine and surgery.”
“Combining anti-obesity medications may achieve much greater pre-surgery weight loss than other methods for those with extreme obesity. Many patients who would otherwise be considered 'too sick for surgery' may now qualify.”
This cohort study investigates the association between preoperative GLP-1 RA use and postoperative weight loss in bariatric surgery patients.
This cohort study investigates the association of weight loss after bariatric surgery and preoperative use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
No takes yet. Share an insight, caveat, or question.
HUYNH et al. (2026) studied this question. Preoperative use of glucagon-like peptide-1 receptor agonists was investigated for its association with weight loss outcomes after bariatric surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: